TO THE EDITOR-Raltegravir is the first human immunodeficiency virus (HIV) integrase strand transfer inhibitor approved by the US Food and Drug Administration and the European Medicines Agency (EMA) for treatment of HIV infection in children [1, 2] . A new pediatric formulation of raltegravir has been introduced with 25-mg and 100-mg tablets that can be chewed or swallowed whole [3] . Peer-reviewed literature on the pharmacokinetics of raltegravir chewable tablets in HIV-infected children is limited to one publication by Nachman et al [4] . They presented the first results of the International Maternal Pediatric Adolescent AIDS Clinical Trials P1066 trial, which is the primary study for approval of raltegravir use in children. A summary of the pharmacokinetic results in children aged ≥2 years is presented in Table 1 [1, [4] [5] [6] . The lowest geometric mean trough level (trough plasma concentration [C trough ]) was observed in children (n = 12) aged 2 to <6 years using chewable tablets. Although the mean C trough (0.0316 mg/L) was above the pharmacokinetic target of 0.015 mg/L (95% inhibitory concentration [IC 95 ] of raltegravir), it was much lower than the reference C trough in adults [5] . The EMA Assessment Report showed that the highest percentage (17%) of patients with a C trough < 0.020 mg/L, which is the suggested threshold from the QDMRK study ( phase III study to compare 800 mg once daily versus 400 mg twice daily raltegravir), was observed in this cohort [1, 6] . Given the limited number of included patients, these results should be interpreted with caution.
In this context, we report a case illustrating our concern of low raltegravir trough levels when using chewable tablets in young HIV-infected children. A 4-yearold HIV-infected patient (17 kg), adopted from sub-Saharan Africa, presented with first-line virologic failure (HIV RNA load >100 000 copies/mL). He switched to the following regimen: raltegravir in the recommended dose of 100 mg (approximately 6 mg/kg) chewable tablets twice daily, together with lamivudine, tenofovir, and ritonavir-boosted lopinavir. We performed therapeutic drug monitoring (TDM) of raltegravir by repeatedly measuring trough levels because virologic efficacy is best correlated with C trough [6] . Despite self-reported good adherence and TDM after observed intake, our patient repeatedly had trough levels below the lower limit of quantification of the assay (<0.014 mg/L), which is below the IC 95 of raltegravir. We adjusted the dosage to 100 mg 3 times daily. Follow-up TDM showed adequate trough values (all ≥0.10 mg/L) with a good clinical response without adverse events. Dosage was further optimized to 75 mg (±4 mg/kg) 3 times daily and trough values remained adequate (range 0.073-0.240 mg/L).
Raltegravir represents a new antiretroviral drug class in pediatric HIV care. Currently, clinical experience with raltegravir chewable tablets is limited. We are concerned that individual children might be exposed to low raltegravir trough values, as illustrated by our case. This could especially be problematic in young children with high viral load. The QDMRK study (800 mg once daily vs 400 mg twice daily) showed that failure to achieve an undetectable viral load appeared predominantly at high baseline viral load and was associated with a lower mean C trough in the oncedaily treatment arm [6] . We believe that additional pharmacokinetic data in HIVinfected children aged 2 to <6 years are needed to reassess optimal dosing in this age group. 
Notes
Table 1. Raltegravir Geometric Mean C trough Values and Corresponding Proportion of Patients With C trough <0.020 mg/L Following Final Recommended Doses of Chewable Tablets and Film-Coated Tablets Twice Daily Cohort or
